Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B
Background Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2 + ) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER-2 + breast cancers...
Gespeichert in:
| Veröffentlicht in: | Clinical and translational medicine 2016-12, Vol.5 (1), p.1-12 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Clinical and translational medicine |
| container_volume | 5 |
| creator | Malecki, Marek Sabo, Chelsea Foorohar, Afsoon Tombokan, Xenia |
| description | Background
Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2
+
) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER-2
+
breast cancers. Although, prophylactic vaccine for human hepatitis B virus (HBV) is very effective.
Specific aim
The specific aim of this work was to design, synthesize, and test bio-molecules which would engage prophylactic immunity against hepatitis B virus towards killing breast cancers cells.
Methods and Results
By biomolecular engineering, we have created a novel family of biomolecules: antibody (anti-HER-2) × vaccine (HBsAg) engineered constructs (AVEC: anti-HER-2 × HBsAg). These biomolecules were utilized for redirecting, accelerating, and amplifying of the vaccination-induced, prophylactic immunity originally targeted against HBV as therapeutic immunity, newly targeted against HER-2
+
breast cancers. Treatment of the HER-2
+
breast cancer cells with AVEC: anti-HER-2 × HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy of killing of HER-2
+
breast cancer cells over that attained with the naked anti-HER-2 antibodies.
Conclusion
Novel antibody-vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying of prophylactic, HBV vaccination-induced immunity as immunotherapy (RAAVIIT) of HER-2
+
breast cancer. We currently streamline this novel therapeutic paradigm into clinical trials of breast and other cancers. |
| doi_str_mv | 10.1186/s40169-016-0111-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4990520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1815698394</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4918-a949c64ef8cd3cdd4ed50bce49420db10f5746e4d7b3acc13f00e9b1f1a972143</originalsourceid><addsrcrecordid>eNqNUU1v1TAQtBCIVqU_gAuyxIVLwJs4iX1BKk98SQUOlLPlOJs8V4kd7KRV_j1-pFQPJASWdm2tZ8brHUKeAnsJIKpXkTOoZJZSCoBMPCCnOWOQQZFXD4_OJ-Q8xmuWluBS1vljcpLXZSHLWp6S_rO_wYFOOujW9iPtfKB2HBfn5z0GPa3Ud7QJqONMjXYGA21Wiq7XvXU9nYKf9uugzWzNxrPzSnWvrUuEPU56trON9M0T8qjTQ8Tzu_2MfHv39mr3Ibv88v7j7uIyM1yCyLTk0lQcO2HawrQtx7ZkjUEuec7aBlhX1rxC3tZNoY2BomMMZQMd6PQz4MUZeb3pTkszYmvQzUEPagp21GFVXlv1-42ze9X7G5VGw8qcJYEXdwLBf18wzmq00eAwaId-iQoElJUUheT_A82FkAUvE_T5H9BrvwSXJpFQvJI1EyATCjaUCT7GgN1938DUwXS1ma5SUgfTlUicZ8cfvmf8sjgBLjbArR1w_bei2l19yr_-rKY41A6P5JtGTHTXYzhq_6-d_QA4R8uN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1846970819</pqid></control><display><type>article</type><title>Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B</title><source>Wiley-Blackwell Journals</source><source>SpringerOpen</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Malecki, Marek ; Sabo, Chelsea ; Foorohar, Afsoon ; Tombokan, Xenia</creator><creatorcontrib>Malecki, Marek ; Sabo, Chelsea ; Foorohar, Afsoon ; Tombokan, Xenia</creatorcontrib><description>Background
Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2
+
) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER-2
+
breast cancers. Although, prophylactic vaccine for human hepatitis B virus (HBV) is very effective.
Specific aim
The specific aim of this work was to design, synthesize, and test bio-molecules which would engage prophylactic immunity against hepatitis B virus towards killing breast cancers cells.
Methods and Results
By biomolecular engineering, we have created a novel family of biomolecules: antibody (anti-HER-2) × vaccine (HBsAg) engineered constructs (AVEC: anti-HER-2 × HBsAg). These biomolecules were utilized for redirecting, accelerating, and amplifying of the vaccination-induced, prophylactic immunity originally targeted against HBV as therapeutic immunity, newly targeted against HER-2
+
breast cancers. Treatment of the HER-2
+
breast cancer cells with AVEC: anti-HER-2 × HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy of killing of HER-2
+
breast cancer cells over that attained with the naked anti-HER-2 antibodies.
Conclusion
Novel antibody-vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying of prophylactic, HBV vaccination-induced immunity as immunotherapy (RAAVIIT) of HER-2
+
breast cancer. We currently streamline this novel therapeutic paradigm into clinical trials of breast and other cancers.</description><identifier>ISSN: 2001-1326</identifier><identifier>EISSN: 2001-1326</identifier><identifier>DOI: 10.1186/s40169-016-0111-8</identifier><identifier>PMID: 27539579</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Breast cancer ; Cancer ; Clinical medicine ; Erb‐B2 ; Hepatitis B ; Hepatitis B virus ; HER‐2 ; Immunotherapy ; Medicine ; Medicine & Public Health ; Mimotope ; Trastuzumab ; Vaccination and Immunotherapy ; Vaccine</subject><ispartof>Clinical and translational medicine, 2016-12, Vol.5 (1), p.1-12</ispartof><rights>The Author(s) 2016</rights><rights>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited</rights><rights>Clinical and Translational Medicine is a copyright of Springer, 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4918-a949c64ef8cd3cdd4ed50bce49420db10f5746e4d7b3acc13f00e9b1f1a972143</citedby><cites>FETCH-LOGICAL-c4918-a949c64ef8cd3cdd4ed50bce49420db10f5746e4d7b3acc13f00e9b1f1a972143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990520/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990520/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11542,27903,27904,41099,42168,45553,45554,46030,46454,51554,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27539579$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malecki, Marek</creatorcontrib><creatorcontrib>Sabo, Chelsea</creatorcontrib><creatorcontrib>Foorohar, Afsoon</creatorcontrib><creatorcontrib>Tombokan, Xenia</creatorcontrib><title>Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B</title><title>Clinical and translational medicine</title><addtitle>Clin Trans Med</addtitle><addtitle>Clin Transl Med</addtitle><description>Background
Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2
+
) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER-2
+
breast cancers. Although, prophylactic vaccine for human hepatitis B virus (HBV) is very effective.
Specific aim
The specific aim of this work was to design, synthesize, and test bio-molecules which would engage prophylactic immunity against hepatitis B virus towards killing breast cancers cells.
Methods and Results
By biomolecular engineering, we have created a novel family of biomolecules: antibody (anti-HER-2) × vaccine (HBsAg) engineered constructs (AVEC: anti-HER-2 × HBsAg). These biomolecules were utilized for redirecting, accelerating, and amplifying of the vaccination-induced, prophylactic immunity originally targeted against HBV as therapeutic immunity, newly targeted against HER-2
+
breast cancers. Treatment of the HER-2
+
breast cancer cells with AVEC: anti-HER-2 × HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy of killing of HER-2
+
breast cancer cells over that attained with the naked anti-HER-2 antibodies.
Conclusion
Novel antibody-vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying of prophylactic, HBV vaccination-induced immunity as immunotherapy (RAAVIIT) of HER-2
+
breast cancer. We currently streamline this novel therapeutic paradigm into clinical trials of breast and other cancers.</description><subject>Breast cancer</subject><subject>Cancer</subject><subject>Clinical medicine</subject><subject>Erb‐B2</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>HER‐2</subject><subject>Immunotherapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mimotope</subject><subject>Trastuzumab</subject><subject>Vaccination and Immunotherapy</subject><subject>Vaccine</subject><issn>2001-1326</issn><issn>2001-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>24P</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNUU1v1TAQtBCIVqU_gAuyxIVLwJs4iX1BKk98SQUOlLPlOJs8V4kd7KRV_j1-pFQPJASWdm2tZ8brHUKeAnsJIKpXkTOoZJZSCoBMPCCnOWOQQZFXD4_OJ-Q8xmuWluBS1vljcpLXZSHLWp6S_rO_wYFOOujW9iPtfKB2HBfn5z0GPa3Ud7QJqONMjXYGA21Wiq7XvXU9nYKf9uugzWzNxrPzSnWvrUuEPU56trON9M0T8qjTQ8Tzu_2MfHv39mr3Ibv88v7j7uIyM1yCyLTk0lQcO2HawrQtx7ZkjUEuec7aBlhX1rxC3tZNoY2BomMMZQMd6PQz4MUZeb3pTkszYmvQzUEPagp21GFVXlv1-42ze9X7G5VGw8qcJYEXdwLBf18wzmq00eAwaId-iQoElJUUheT_A82FkAUvE_T5H9BrvwSXJpFQvJI1EyATCjaUCT7GgN1938DUwXS1ma5SUgfTlUicZ8cfvmf8sjgBLjbArR1w_bei2l19yr_-rKY41A6P5JtGTHTXYzhq_6-d_QA4R8uN</recordid><startdate>201612</startdate><enddate>201612</enddate><creator>Malecki, Marek</creator><creator>Sabo, Chelsea</creator><creator>Foorohar, Afsoon</creator><creator>Tombokan, Xenia</creator><general>Springer Berlin Heidelberg</general><general>John Wiley & Sons, Inc</general><scope>C6C</scope><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>201612</creationdate><title>Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B</title><author>Malecki, Marek ; Sabo, Chelsea ; Foorohar, Afsoon ; Tombokan, Xenia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4918-a949c64ef8cd3cdd4ed50bce49420db10f5746e4d7b3acc13f00e9b1f1a972143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Breast cancer</topic><topic>Cancer</topic><topic>Clinical medicine</topic><topic>Erb‐B2</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>HER‐2</topic><topic>Immunotherapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mimotope</topic><topic>Trastuzumab</topic><topic>Vaccination and Immunotherapy</topic><topic>Vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malecki, Marek</creatorcontrib><creatorcontrib>Sabo, Chelsea</creatorcontrib><creatorcontrib>Foorohar, Afsoon</creatorcontrib><creatorcontrib>Tombokan, Xenia</creatorcontrib><collection>SpringerOpen</collection><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malecki, Marek</au><au>Sabo, Chelsea</au><au>Foorohar, Afsoon</au><au>Tombokan, Xenia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B</atitle><jtitle>Clinical and translational medicine</jtitle><stitle>Clin Trans Med</stitle><addtitle>Clin Transl Med</addtitle><date>2016-12</date><risdate>2016</risdate><volume>5</volume><issue>1</issue><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>2001-1326</issn><eissn>2001-1326</eissn><abstract>Background
Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2
+
) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER-2
+
breast cancers. Although, prophylactic vaccine for human hepatitis B virus (HBV) is very effective.
Specific aim
The specific aim of this work was to design, synthesize, and test bio-molecules which would engage prophylactic immunity against hepatitis B virus towards killing breast cancers cells.
Methods and Results
By biomolecular engineering, we have created a novel family of biomolecules: antibody (anti-HER-2) × vaccine (HBsAg) engineered constructs (AVEC: anti-HER-2 × HBsAg). These biomolecules were utilized for redirecting, accelerating, and amplifying of the vaccination-induced, prophylactic immunity originally targeted against HBV as therapeutic immunity, newly targeted against HER-2
+
breast cancers. Treatment of the HER-2
+
breast cancer cells with AVEC: anti-HER-2 × HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy of killing of HER-2
+
breast cancer cells over that attained with the naked anti-HER-2 antibodies.
Conclusion
Novel antibody-vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying of prophylactic, HBV vaccination-induced immunity as immunotherapy (RAAVIIT) of HER-2
+
breast cancer. We currently streamline this novel therapeutic paradigm into clinical trials of breast and other cancers.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27539579</pmid><doi>10.1186/s40169-016-0111-8</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2001-1326 |
| ispartof | Clinical and translational medicine, 2016-12, Vol.5 (1), p.1-12 |
| issn | 2001-1326 2001-1326 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4990520 |
| source | Wiley-Blackwell Journals; SpringerOpen; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; PubMed Central; EZB Electronic Journals Library |
| subjects | Breast cancer Cancer Clinical medicine Erb‐B2 Hepatitis B Hepatitis B virus HER‐2 Immunotherapy Medicine Medicine & Public Health Mimotope Trastuzumab Vaccination and Immunotherapy Vaccine |
| title | Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A59%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20paradigm%20for%20immunotherapy%20of%20breast%20cancer%20by%20engaging%20prophylactic%20immunity%20against%20hepatitis%20B&rft.jtitle=Clinical%20and%20translational%20medicine&rft.au=Malecki,%20Marek&rft.date=2016-12&rft.volume=5&rft.issue=1&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=2001-1326&rft.eissn=2001-1326&rft_id=info:doi/10.1186/s40169-016-0111-8&rft_dat=%3Cproquest_pubme%3E1815698394%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1846970819&rft_id=info:pmid/27539579&rfr_iscdi=true |